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Abstract
Introduction The present study was conducted to investigate if
chromosome band 3p14 is of any pathogenic significance in the
malignant process of breast cancer. Genetic studies have
implicated a tumour suppressor gene on chromosome arm 3p
and we have proposed LRIG1 at 3p14 as a candidate tumour
suppressor. The LRIG1 gene encodes an integral membrane
protein that counteracts signalling by receptor tyrosine kinases
belonging to the ERBB family. LRIG1 mRNA and protein are
expressed in many tissues, including breast tissue.
Methods In the present report we analysed the LRIG1 gene by
fluorescence  in situ hybridisation (FISH), LRIG1  mRNA by
quantitative RT-PCR, and LRIG1 protein by western blot
analysis. Two tumour series were analysed; one series
consisted of 19 tumour samples collected between 1987 and
1995 and the other series consisted of 9 tumour samples with
corresponding non-neoplastic breast tissues collected
consecutively.
Results The LRIG1 gene showed increased copy number in 11
out of 28 tumours (39%) and only one tumour showed a
deletion at this locus. Increased LRIG1  copy number was
associated with increased levels of LRIG1 mRNA (two of three
tumours) and protein (four of four tumours) in the tumours
compared to matched non-neoplastic breast tissue, as
assessed by RT-PCR and western blot analysis.
Conclusion The molecular function of LRIG1 as a negative
regulator of ERBB receptors questions the biological
significance of increased LRIG1 copy number in breast cancer.
We propose that a common, but hitherto unrecognised, breast
cancer linked gene is located within an amplicon containing the
LRIG1 locus at 3p14.3.
Introduction
Breast cancer is a major cause of death among women. In
order to provide optimal treatment, prognostic factors, such as
lymph node status and steroid receptor expression, are widely
used. In recent years, genetic approaches studying chromo-
somal aberrations have been suggested as a tool in the proc-
ess to individualise the adjuvant treatment given to patients.
Several studies have been published during the past years
with a focus on identifying the genes that contribute to initia-
tion and clinical progression of breast cancer [1,2].
Identification of a germline mutation of BRCA1 at 17q21 [3]
and BRCA2 at 13q12-13 [4] has been an important finding in
studies of hereditary breast cancer. Epidermal growth factor
receptor (EGFR/ERBB1) and ERBB2 (also known as HER2)
overexpression [5-7], p53 inactivation [8,9] and nm23 overex-
pression [10] also seem to be of clinical prognostic impor-
tance. Chromosomal amplifications have been described in
breast cancer for several genes, including MYC at 8q24 and
ERBB2  at 17q11.2 [11,12]. Other amplified chromosomal
areas detected in breast cancer are 13q31, 17q22-24, 1q41-
44 and 20q13. In general, gene amplifications are considered
late events in cancerogenesis, even though much is still
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unknown about the importance of amplifications of specific
genes. In breast cancer, amplification of ERBB2 correlates
with a worse prognosis [13] and amplification of C-MYC is
associated with progression from carcinoma in situ to invasive
breast cancer [14]. Cytogenetic analyses of tumours have
shown that chromosome 1 is the most frequently altered chro-
mosome in breast cancer [15]. In other breast cancer studies,
loss of heterozygosity (LOH) at 3p was the most common
chromosomal aberration [16-18]. In a study by Maitra et al.
[19], LOH in the 3p area was apparent in 87% of breast
tumours, and LOH at 3p14.3 in 41% of the tumours. The short
arm of chromosome 3 thus likely harbours at least one tumour
suppressor gene [20]. The FHIT gene localized to 3p14.2,
which frequently shows LOH, is also suggested to be a prog-
nostic factor in breast cancer [21,22].
Recently, the human gene LRIG1  (leucine-rich and immu-
noglobulin-like domains 1) was described and localised to
chromosome 3p14.3 [23,24]. The LRIG1 gene encodes a
protein with extracellular leucine-rich repeats and immu-
noglobulin-like domains, a transmembrane part, and a cyto-
plasmic tail. LRIG1 acts as a negative regulator of ERBB1-4
by enhancing receptor ubiquitylation and degradation [25,26].
The mechanism involves the recruitment of c-Cbl, an E3 ubiq-
uitin ligase that simultaneously ubiquitylates EGFR and LRIG1
and sorts them for degradation [25].
The role of LRIG1 as a part of a group of proteins that help
desensitize receptor tyrosine kinase (RTK) signalling makes it
important to study the expression and role of LRIG1 in tumours
in which the ERBB receptors have clinical relevance.
The present study was conducted to investigate if the LRIG1
gene, mRNA, or protein was deleted or dysregulated in human
breast cancer. The LRIG1  locus was analysed by fluores-
cence in situ hybridisation (FISH), mRNA was quantified by
real-time RT-PCR and protein was analysed by western blot
analysis. To further explore how LRIG1 expression was related
to growth factor receptor expressions, quantitative RT-PCR of
EGFR and ERBB2 was performed. We report an unexpected
increase in copy number of the LRIG1 locus in 39% of the
breast tumours, implicating a breast cancer gene at, or close
to, 3p14.3.
Materials and methods
Patients and sample preparation
Previously collected (1986 to 1995) samples from 19 patients
were included in a first examination (group A). Tumour sam-
ples and non-neoplastic breast tissue were then collected
from nine patients with breast carcinoma (group B). Clinical
characteristics of the patients are presented in Table 1. The
study was approved by the local ethics committee. None of the
patients had received any treatment prior to specimen collec-
tion. In group B, samples of the tumour and a piece of the non-
neoplastic breast tissue were collected immediately after exci-
sion, one part of each frozen in liquid nitrogen and stored at -
80°C, and another part stored in RNAlater (Ambion inc, Aus-
tin, Texas, USA). The other adjacent parts of the tissue sam-
ples were fixed in formalin, paraffin embedded and used for
routine morphological examination and tumour grading
(according to Page et al. [27]), immunohistochemical staining
and tumour tissue array construction. The preparation of RNA
was performed as previously described [23].
FISH
Freshly frozen breast cancer tissues were disintegrated in
methanol:acetic acid solution (3:1; Carnoy's solution) on ice.
The nuclei were collected by passing the disintegrated tissues
through a nylon mesh (pore size 70 µm) and then centrifuged.
Cells were washed in methanol:acetic acid solution (3:1) two
to three times at room temperature. FISH slides were prepared
by dropping the cell suspension onto glass slides. After air-
drying, FISH-slides were immediately used or stored at -20°C.
Before hybridisation, FISH-slides were incubated in 75 mM
KCl for 20 minutes at 37°C and fixed in Carnoy's solution for
5 minutes at room temperature. After fixation, FISH slides were
treated with RNAase (100 µg/ml) for 1 h, followed by washing
in 2 × SSC (saline sodium citrate) three times for 2 minutes
each time. Finally, the slides were incubated in solution con-
taining 100 µg/ml pepsin in 10 mM HCl for 10 minutes, fol-
lowed by incubation in PBS for 5 minutes at room temperature
and stepwise dehydration in alcohol (70%, 80%, 95%). The
BAC clone 751k5 (Invitrogene, Carlsbad, USA), containing
the LRIG1, was used as the FISH probe. DNA was labelled by
nick translation using Spectrum Orange according to the man-
ufacturer's protocol (Abbot Diagnostics, Wiesbaden-Delken-
heim, Germany). Probe (10 µl) containing 100 ng DNA, 5 µl
Cot-1 DNA in 60% formamide was pre-incubated for 1 h at
37°C and then applied to each slide. Probe and target DNA
were denatured simultaneously for 3 minutes at 72°C. Slides
were hybridised overnight at 37°C in a humidity chamber.
Post-hybridisation washing was performed in 2 × SSC con-
taining 0.3% NP-40. Nuclear counterstaining was done with
DAPI solution for 2 minutes. As control, a centromere probe
for chromosome 3 was included in the hybridisation solution.
In each case, LRIG1 and CEP3 signals were counted in 100
to 200 nuclei by two independent investigators. The presence
of at least three signals in more than 20% of the nuclei was the
criteria for scoring an increased copy number of LRIG1. Anal-
ysis was performed using an Axioplan 2 microscope (Carl
Zeiss Vision, Hallbergmoos, Germany.) Digital images were
captured and stored using Cytovision software (Applied Imag-
ing Corporation, San Jose, USA).
Cell lines
The breast cancer cell lines MDA-MB-231, MDA-MB-415 and
HS 578T were obtained from American type culture collection
(Manassas, VA, USA) and ZR-75-1 was kindly provided by Dr
J Bergh (Uppsala University, Sweden). The breast cancer cellAvailable online http://breast-cancer-research.com/content/7/5/R719
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lines were cultivated in Dulbecco's modified Eagles medium,
supplemented with 10% w/v fetal bovine serum and 50 µg/ml
gentamicin from Invitrogen AB (Täby, Sweden). The immortal-
ised mammary epithelial cell line hTERT-HME1 was obtained
from BD Bioscencies Clontech (Stockholm, Sweden) and cul-
tivated according to the manufacurer's instructions by using
media and supplements from Clonetics, Bio Whittaker (Walk-
ersville, MD, USA).
Quantitative RNA analysis
RNA was prepared from tissue samples by using RNAqueous
kit (Ambion inc, Austin, Texas, USA), according to the manu-
facturer's instructions. Real-time quantitative RT-PCR was
performed as previously described [28].
Western blot analysis
Cell lysates, protein concentrates and immunoprecipitated
material were incubated in LDS (lithium dodecyl sulfate) sam-
ple buffer for 10 minutes at 70°C followed by electrophoresis
on 3% to 8% TRIS-acetate NuPAGE gradient gel. The pro-
teins were thereafter transferred to polyvinylidene difluoride
membranes by using an Xcell II Mini-Gel blot module. Gel
apparatus, gels, buffers, blotting module, and membranes
were from Invitrogen. Non-specific binding was blocked by
using incubation of the membranes with 5% w/v non-fat milk
powder in TBS containing 0.1% w/v Tween-20. The mem-
branes were thereafter incubated with the primary antibodies
at 1 µg/ml followed by peroxidase-conjugated secondary
antibodies (Amersham Pharmacia Biotech, Amersham Bio-
sciences, New Jersey, USA). The primary antibodies used
were LRIG1-151 [24] and rabbit anti-actin (Sigma-Aldrich St.
Louis, Missouri, USA). Visualization was performed by using
the enhanced chemiluminescense system ECL-plus, (ECL-
advanced and hyperfilm ECL Blotting Detection system kit,
Amersham Biosciences, New Jersey, USA). The samples were
diluted stepwise by approximately 50% in 3 to 4 steps. The
results were analysed visually by three separate investigators
and an apparent change between tumour and non-neoplastic
tissue of at least 50% was considered convincing.
Results
FISH analysis of archived breast cancer samples
To evaluate the number of LRIG1 gene copies, FISH was per-
formed on cell nuclei from the archived breast cancer samples
(group A). An increased copy number of LRIG1 was seen in
more than 20% of the nuclei in 7 of the 19 tumours (in most
cells three to five signals). The fraction of tumour cells with
increased copy number varied between 23% and 79%. Nor-
mal signal pattern corresponding to two copies per nucleus
was detected in 11 of the 19 tumours, and 1 tumour demon-
strated decreased copy number of LRIG1 (Table 2).
Table 1
Clinical characteristics of the 28 breast tumours included in the study
n % of total Tumours with increased LRIG1 copy 
number (n = 11)
Tumours without increased LRIG1 copy 
number (n = 17)
Tumour type
Ductal 21 75 10 (82 %) 11(65%)
Lobular 2 7 1 1
Mixed group 4 14 0 4
Medullar 1 4 0 1
Axillar lymph node
Negative 17 61 6 (54%) 11 (65%)
Positive 10 36 5 (45%) 5 (29%)
Missing value 1 4 0 1
Estrogen receptor
Positive 21 75 8 (73%) 13 (76%)
Negative 4 14 2 (9%) 2 (12%)
Missing value 3 11 1 2 (12%)
Progesterone receptor
Positive 18 64 6 (54%) 12 (70%)
Negative 5 18 3 (27%) 2 (28%)
Missing value 5 18 2 (18%) 3 (18%)
Outcome=deceased 10 36 3 (27%) 7 (41%)Breast Cancer Research    Vol 7 No 5    Ljuslinder et al.
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FISH Analysis of Fresh Tumour Samples and Breast Cell 
lines
FISH analysis revealed increased copy numbers of LRIG1 in
four of the nine tumours from group B (example shown in Fig.
1a). The fraction of tumour cells with increased copy number
varied between 21% and 49%. Normal signal pattern corre-
sponding to two LRIG1 copies per nucleus was detected in
the remaining five tumours (Table 2). A parallel FISH analysis
including 10 tumours of a different tissue origin showed no
aberrations of LRIG1 gene copy numbers in these tumours
(ongoing study, data not shown). In one of the breast tumours
with increased copy number of LRIG1 (patient B8), a more
detailed FISH analysis was performed to assess the chromo-
some 3 status and the ploidity of the tumour cells. This
showed that the LRIG1 copy number was increased (Fig. 1a)
but the chromosome 3 centromere was not (Fig. 1b). Further-
more, by using a mixture of LRIG1 probe and a specific 3p
subtelomere probe (probe position 30 tel (D3S4559); Abbot
Vysis), no increased copy number was found for the 3p subte-
lomeric region either (Fig. 1c). No evidence of aneuploidy was
found, as analysed by using centromere probes for chromo-
somes 3, 18 and X (Fig. 1d).
FISH analysis was also performed on the breast cancer cell
lines MDA-MB-231, MDA-MB-415, HS 578T and ZR-75-1,
and the immortalised mammary epithelial cell line hTERT-
HME1. Increased copy number of LRIG1 was found in three
of the five cell lines (MDA-MB-231, HS 578T and hTERT-
HME1), whereas decreased copy number was found in the
MDA-MB-415 cell line. A normal FISH signal pattern for
LRIG1 was present in ZR-75-1.
Quantitative RT-PCR
Quantitative RT-PCR was performed on RNA extracted from
tumour tissue and non-neoplastic tissue from seven of the nine
patients in group B (the quality of the samples from two of the
patients was not adequate for quantitative RT-PCR analysis).
A fibroadenosis was also examined, with collected pieces
both from the fibroadenosis and the surrounding tissue. The
expression levels in different parts of the healthy breast tissue
from the same individual did not differ by more than 20% (data
not shown) and, therefore, a 20% cut-off level was used for
both overexpression and underexpression. The ratio between
the expression in the tumour and non-neoplastic tissue was
calculated and ratios >1.2 were regarded as significant
tumour overexpression and ratios <0.8 were regarded as sig-
nificant tumour underexpression. LRIG1 mRNA was signifi-
cantly overexpressed in two of the seven tumours and
significantly underexpressed in two of the seven tumours
(Table 3). The three tumours with increased LRIG1  copy
number (FISH analysis) that were able to be analysed by RT-
PCR for LRIG1 showed significant overexpression of LRIG1
mRNA in two cases. Four tumours with increased LRIG1 copy
number were analysed by RT-PCR for EGFR/ERBB1, and all
four showed significantly lower expression of EGFR/ERBB1
and three showed significantly higher expression of ERBB2
than their matched normal controls (Table 4). Two of the
Table 2
FISH analysis of the LRIG1 locus in 28 breast cancer tumours
FISH 3p14.3 Group A (n = 19) Group B (n = 9)
Increased copy number 7 (36 %) 4 (44%)
Normal copy number 11 (57%) 5 (55%)
Decreased copy number 1 (5%) 0
Group A: tumours collected 1986 to 1996 retrospectively. Group B: tumours collected 2002 to 2003 prospectively.
Figure 1
FISH analysis of breast cancer cells from patient B8 FISH analysis of breast cancer cells from patient B8. (a) Analysis with a 
specific LRIG1 (red) probe showing increased gene copy number 
(more than two copies) of the LRIG1 gene at 3p14. (b) Analysis with a 
specific CEP3 (centromeric chromosome 3; red) probe, showing no 
additional chromosome 3. (c) Analysis with a specific 3p subtelomeric 
probe (green) and LRIG1 (red) mixture showing increased gene copy 
number of the LRIG1 gene but only two copies of the 3p arm. (d) Anal-
ysis with a mixture of probes for CEP3 (red), X chromosome (green) 
and chromosome 18 (blue), showing no aneuploidy for these 
chromosomes.Available online http://breast-cancer-research.com/content/7/5/R719
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tumours without increased LRIG1 copy number also had low-
ered EGFR expression.
Western blot analysis of fresh tumour samples and their 
matched non-neoplastic breast tissue
In group B, five of the nine tumours overexpressed the LRIG1
protein compared to their matched non-neoplastic tissues as
analysed by western blotting. Four of these five tumours also
displayed increased LRIG1 copy number (Fig. 2, Table 3).
Thus, all of the tumours with increased LRIG1 copy number
overexpressed LRIG1 as determined by western blot analysis,
but also one tumour with normal LRIG1 copy number showed
high levels of the protein by western blotting.
Combined analysis of group A and B
In total, 28 breast tumours were analysed by FISH with LRIG1
specific probe. A normal signal pattern, corresponding to two
LRIG1 copies per nucleus, was detected in 16 cases. In 11
out of 28 tumours (39%), an increased number of LRIG1 sig-
nals were found (Table 2, Fig. 1a). The fraction of tumour cells
with increased copy number varied between 21% and 79%.
Complementary FISH analyses showed that there was no
increase in the copy number of the entire 3p arm (Fig. 1b–d).
As seen by quantitative RT-PCR analysis, two out the three
analysed tumours with increased LRIG1  copy number (in
group B) showed higher expression of LRIG1 mRNA than the
matched non-neoplastic breast tissues. In all four tumours with
increased LRIG1 copy number, expression of LRIG1 protein
was higher than in the matched non-neoplastic breast tissue,
as assessed by western blot analysis.
Complementary analysis of five transformed breast cancer cell
lines showed similar results, with three of them showing an
increased copy number of the 3p14 locus.
Discussion
This novel investigation of 3p14 demonstrated unexpectedly
an increased copy number of the proposed tumour suppres-
sor gene LRIG1 in 39% (11/28) of the breast tumours and in
60% (3/5) of the breast cancer cell lines. The malignant proc-
ess is believed to be driven by genetic diversification through
mutations, deletions and amplifications followed by natural
selection of surviving and proliferating cancer cells. One result
of this process is the enrichment of amplicons harbouring
tumour promoting genetic elements, that is, cancer associated
genes. Accordingly, the presented results imply that a com-
mon, but hitherto unrecognised, breast cancer related gene
was located within an amplicon that included the LRIG1 locus
at 3p14.
Despite numerous genetic studies, increased copy number at
the 3p14 locus has, to our knowledge, never previously been
reported in primary human breast tumours. Interestingly, how-
ever, amplifications at 3p14 have recently been reported in
breast cancer-derived cell lines [29,30]. Previous comparative
genomic hybridisation (CGH) studies of 3p have generally
shown losses and only rarely gains [31]. There are at least four
possible explanations why the herein demonstrated increased
copy number at 3p14 has not previously been described. First,
the area of increased copy number could be relatively small,
and so escaped detection by conventional analyses. Second,
most studies of this chromosomal area have analysed LOH,
and thus have not addressed possible gene amplifications.
Third, results obtained by conventional CGH, a method fre-
Table 3
Summary of FISH, western blot and RT-PCR analysis of LRIG1 in nine breast cancer tumours
Patient no. FISHa Western blotb LRIG1 RT-PCR (T/NN)c
B1 I In 1.45d
B2e II n -
B3e NL E -
B4 NL D 0.85
B5 I In 1.63d
B6 NL E 0.50d
B7 NL In 0.36d
B8 I In 1.13
B9 NL E 1.17
aFISH: I, increased LRIG1 copy number; NL, normal LRIG1 copy number. bWestern blot: comparison of the staining in tumour tissue (T) and non-
neoplastic tissue (NN). A visual increase (In)/decrease (D) of at least 50% was considered convincing. E, equal levels of protein. cLRIG1 RT-PCR 
T/NN; LRIG1 mRNA expression level in neoplastic (T) tissue samples divided by levels in matched non-neoplastic (NN) tissue samples. dAs 
described in the results, at p.9, ratios >1.2 are regarded as significant overexpression and ratios <0. 8 are regarded as significant 
underexpression in neoplastic tissue compared to non-neoplastic tissue. Samples were consecutively collected. eTwo tumours did not yield RNA 
of sufficient quality for the RT-PCR analysis.Breast Cancer Research    Vol 7 No 5    Ljuslinder et al.
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quently used to detect both gains and losses, are usually
difficult to interpret in chromosomal regions close to the
centromere, such as the LRIG1 locus at 3p14. By employing
an alternative CGH methodology using cDNA arrays, an ampli-
con at 3p14 was described in breast cancer-derived cell lines
[29]. Whether this region is co-duplicated with LRIG1 at 3p14
has not been addressed but will be the subject of future stud-
ies. Finally, a further limitation of conventional and array based
CGH methodologies is that they evaluate the mean gene copy
number in the analysed sample. FISH, in contrast, has single
cell resolution and, thus, is more sensitive and able to detect
modest gene copy number changes that could involve only a
minority of the tumour cells.
An important question regarding the herein discovered ampli-
con is its size and the identity of the underlying possible breast
cancer gene(s). We have shown by FISH that the area of
increased copy number contained LRIG1 at 3p14 but was
lacking the centromere and the subtelomeric region of chro-
mosome 3. In addition, as discussed above, chromosome 3
has previously been extensively studied by CGH, which rules
out the possibility of a common amplicon spanning centro-
mere-distal regions of 3p. From this, we estimate that the puta-
tive breast cancer gene is located on chromosome 3,
somewhere between the centromere and 3p21. Obviously,
the only gene directly demonstrated so far to be duplicated in
the analysed breast tumours was LRIG1. This raises the ques-
tion of whether LRIG1 itself is a breast cancer gene. LRIG1
has been proposed to interact with and counteract the effects
of growth factor receptors such as EGFR/ERBB1 [23,32],
thereby functioning as a tumour suppressor. This hypothesis
was recently confirmed by molecular studies showing that
LRIG1 downregulates ERBB1-4 by enhancing receptor
degradation [25,26]. Because EGFR/ERBB1 and ERBB2 are
important and frequently overexpressed breast cancer genes,
it is unlikely that LRIG1, as an ERBB antagonist, is a tumour
promoter. Of course, we cannot exclude that LRIG1 might
have other functions, which for tumour promotion could domi-
nate over its ERBB-antagonising effects. According to a
recent estimate [33], however, there are 80 genes in addition
to LRIG1 in the region between the centromere and 3p21
(coordinates 64M-92M), the gene copy numbers of which
could potentially have been increased in conjuction with
LRIG1. These genes encode a variety of different kinds of pro-
teins, of known and unknown functions, including a tyrosine
kinase receptor (EPHA3), a protein phosphatase regulatory
subunit (PPP4R2), an ubiquitin-conjugating enzyme (UBE1C),
and different transcription factors (e.g. TMF1, FOXP1 and
POU1F1). The amplicon described by Hyman et al. [29] is
confined to a 2.7 mb region (coordinates 72M-75M), which
include 13 genes but not LRIG1 at 66M. Moreover, an ampli-
con close to the LRIG1 locus with the coordinates 60M-64M
was recently described in breast cancer cell line MCF-7 [30].
This amplicon contains about 17 genes. Whether the regions
at 72M-75M and 60M-64M are increased in copy number in
Figure 2
Western blot analyses of LRIG1 in the nine breast cancer patients in  group B Western blot analyses of LRIG1 in the nine breast cancer patients in 
group B. Tumours (T) versus non-neoplastic breast tissue (NN). West-
ern blot analysis was performed on samples with primary antibodies 
LRIG1-151 and anti-rabbit anti-actin. A visual change of at least 50% 
was considered convincing, as determined by three different investiga-
tors. Pat, patient number.Available online http://breast-cancer-research.com/content/7/5/R719
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conjunction with the LRIG1 locus at 66M was not addressed
in the present study but will be the subject of future studies.
Clearly, a more refined mapping of the area of increased copy
number and functional studies of candidate genes are needed
for defining the hypothesised breast cancer gene(s). We
conclude, nevertheless, that a common but hitherto unrecog-
nised breast cancer gene is located at or near the LRIG1
locus.
Increased  LRIG1  copy number as detected by FISH was
associated with increased mRNA and protein levels in tumours
compared to non-neoplastic breast tissue, as determined by
quantitative RT-PCR and western blot analysis (Table 3). A
concordance between gene overexpression and enhanced
mRNA levels is often, but not always, observed [29].
Because ERBB family members are strongly implicated in the
aetiology of breast cancer, and because ERBB proteins and
LRIG1 interact at the molecular level, we analysed the expres-
sion of EGFR/ERBB1 and ERBB2 mRNA. Intriguingly, EGFR/
ERBB1 mRNA was significantly underexpressed in all of the
four tumours analysed with increased LRIG1 copy number. Of
these four tumours, three showed significant overexpression
of ERBB2 mRNA. EGFR/ERBB1 is overexpressed in 35% to
60% of breast cancers, which correlates with a negative
steroid receptor status, increased ERBB2 and VEGF (Vascu-
lar endothelial growth factor) expression [7]. The impact of
EGFR/ERBB1 overexpression on clinical outcome has not
been completely clarified, but in most studies it is considered
to be a negative prognostic factor [34]. The combination of
increased LRIG1 copy number and protein expression and
Table 4
EGFR and ERBB2 quantitative RT-PCR mRNA results in eight patients and matched controls (group B)
Patient number T NN T/NNa
1b
EGFR 4,677 12,493 0.37
ERBB2 24,066 21,817 1.1
2b
EGFR 3,321 14,519 0.22
ERBB2 61,389 6,666 9.2
4
EGFR 20,778 14,842 1.39
ERBB2 9,143 6,742 1.35
5b
EGFR 9,730 15,867 0.61
ERBB2 13,506 3,056 4.41
6
EGFR 1,305 15,871 0.08
ERBB2 10,677 10,080 1.06
7
EGFR 1,024 12,162 0.08
ERBB2 7,639 5,871 1.30
8b
EGFR 4,936 28,111 0.17
ERBB2 17,106 9,263 1.85
9
EGFR 5,540 1,437 3.85
ERBB2 7,330 5,540 1.32
aT/NN: mRNA expression levels of LRIG1 in tumour tissue (T) samples divided by values in matched non-neoplastic (NN) tissue samples. As 
described in the results, at p.9, ratios >1. 2 are regarded as significant overexpression and ratios <0. 8 are regarded as significant 
underexpression in neoplastic tissue compared to non-neoplastic tissue. bPatients with increased LRIG1 copy number. No RNA from patient 3 
was available for EGFR/ERBB2 analysis.Breast Cancer Research    Vol 7 No 5    Ljuslinder et al.
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low EGFR/ERBB1 expression might represent a subtype of
breast cancer with its own clinical features. To reveal such a
biological subtype, a larger number of tumours must be
examined.
Conclusion
We have described, for the first time, frequent increased copy
number at 3p14.3 in breast cancer. This attributes a breast
cancer associated gene to 3p14 or surrounding plausibly co-
amplified regions. In future studies, it will be important to
define the genetic element, that is, the breast cancer gene(s)
underlying the observed copy number increase, and to exam-
ine a greater number of tumours in order to evaluate its clinical
significance.
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